CSVD负担是否修饰双联抗血小板疗效:INSPIRES试验事后分析
该研究为INSPIRES试验的事后亚组分析,纳入5126例轻型卒中或高危TIA患者,按改良CSVD评分分为0-2分与≥3分两组,评估氯吡格雷联合阿司匹林对比阿司匹林的疗效与安全性。结果未观察到抗血小板治疗与CSVD评分组间的显著交互作用,提示两组的获益-风险特征可能无显著差异。
要点
- CSVD评分≥3组90天卒中复发率数值上高于0-2组(9.10% vs 8.05%)。
- 氯吡格雷联合阿司匹林在CSVD 0-2组和≥3组降低卒中复发的相对程度相似,交互P=0.84。
- 氯吡格雷联合阿司匹林在两组增加出血风险的相对程度相似,交互P=0.68。
核心结论
- 未观察到抗血小板治疗与改良CSVD评分之间的显著交互作用,提示氯吡格雷联合阿司匹林在CSVD评分0-2分与≥3分患者中的获益-风险特征可能无显著差异。
研究设计与样本
- INSPIRES试验的事后亚组分析,该试验为双盲、安慰剂对照、2×2析因设计的随机临床试验,在中国222个中心于2018年9月至2022年10月开展。
- 共纳入5126例患者(中位年龄65[57-71]岁;男性3915例[64.2%]),其中2131例(41.57%)改良CSVD评分≥3。
- 根据不含微出血的改良CSVD负担评分将患者分为0-2分和≥3分两组。
主要发现
- CSVD评分≥3组90天内卒中复发率数值上高于0-2组(9.10% vs 8.05%),中重度出血风险数值上低于0-2组(0.56% vs 0.80%)。
- 氯吡格雷联合阿司匹林对比阿司匹林降低卒中复发:CSVD 0-2组校正HR 0.78(95%CI 0.61-1.01;P=0.06),CSVD≥3组校正HR 0.82(95%CI 0.62-1.09;P=0.12),交互P=0.84。
- 氯吡格雷联合阿司匹林对比阿司匹林增加出血风险:CSVD 0-2组校正HR 2.83(95%CI 1.52-5.27;P=0.03),CSVD≥3组校正HR 2.13(95%CI 1.08-4.19;P=0.22),交互P=0.68。
关键数值与推荐
- 主要疗效与安全结局为90天随访内的卒中复发和中重度出血风险。
- 采用Cox比例风险模型检验治疗与CSVD分组的交互作用。
临床怎么用
- 对于轻型卒中或高危TIA患者,氯吡格雷联合阿司匹林对比阿司匹林的获益-风险特征在改良CSVD评分0-2分与≥3分患者中可能无显著差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of cerebral small vessel disease (CSVD) imaging markers is high, yet their influence on stroke prognosis remains unclear. This study aimed to estimate the effects of CSVD on the efficacy and safety of clopidogrel+aspirin versus aspirin among patients with minor stroke or high-risk transient ischemic attack. METHODS: This was a post hoc subgroup analysis of the INSPIRES trial (Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis), which was a double-blind, placebo-controlled, 2×2 factorial, and randomized clinical trial conducted at 222 centers in China from September 2018 to October 2022. Patients were classified into CSVD score 0 to 2 and CSVD score ≥3 groups based on a modified CSVD burden score without microbleeds. The primary efficacy and safety outcomes were stroke recurrence and moderate-to-severe bleeding risk within 90-day follow-up. We used Cox proportional hazards models to test the treatment-by-CSVD group interaction for stroke and bleeding risk. RESULTS: A total of 5126 patients (median age, 65 [57-71] years; 3915 [64.2%] males) were enrolled and 2131 (41.57%) had a modified CSVD score ≥3. Patients with CSVD score ≥3 had numerically higher stroke recurrence rate (9.10% versus 8.05%) and lower risk of moderate-to-severe bleeding (0.56% versus 0.80%) than those with CSVD score 0 to 2 within 90 days. Clopidogrel+aspirin versus aspirin reduced stroke recurrence to a similar relative degree in both CSVD score 0 to 2 (adjusted hazard ratio, 0.78 [95% CI, 0.61-1.01]; P=0.06) and CSVD score ≥3 groups (adjusted hazard ratio, 0.82 [95% CI, 0.62-1.09]; P=0.12) with no evidence of statistical interaction (P=0.84). Clopidogrel+aspirin versus aspirin increased bleeding risk to a similar relative degree in both CSVD score 0 to 2 (adjusted hazard ratio, 2.83 [95% CI, 1.52-5.27]; P=0.03) and CSVD score ≥3 groups (adjusted hazard ratio, 2.13 [95% CI, 1.08-4.19]; P=0.22) with no statistical interaction (P=0.68). CONCLUSIONS: In this post hoc subgroup analysis, no significant interaction effect was observed between the antiplatelet treatment and the modified CSVD score, suggesting that clopidogrel+aspirin may not provide a significantly different benefit-risk profile across patients with CSVD score 0 to 2 versus CSVD score ≥3. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635749.
引用
- Li H, Cheng M, Gao Y, et al. Does the Burden of CSVD Modify the Efficacy of Dual Antiplatelet Therapy?: A Post Hoc Analysis of the INSPIRES Trial. Stroke. 2025. PMID: 40190261. doi:10.1161/STROKEAHA.124.049826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。